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Abstract
Background: Dupuytren's disease of the hand is a common condition affecting the palmar fascia, resulting in
progressive flexion deformities of the digits and hence limitation of hand function. The optimal treatment remains
unclear as outcomes studies have used a variety of measures for assessment.
Methods: A literature search was performed for all publications describing surgical treatment, percutaneous needle
aponeurotomy or collagenase injection for primary or recurrent Dupuytren’s disease where outcomes had been
monitored using functional measures.
Results: Ninety-one studies met the inclusion criteria. Twenty-two studies reported outcomes using patient
reported outcome measures (PROMs) ranging from validated questionnaires to self-reported measures for return to
work and self-rated disability. The Disability of Arm, Shoulder and Hand (DASH) score was the most utilised patient-
reported function measure (n=11). Patient satisfaction was reported by eighteen studies but no single method was
used consistently. Range of movement was the most frequent physical measure and was reported in all 91 studies.
However, the methods of measurement and reporting varied, with seventeen different techniques being used.
Other physical measures included grip and pinch strength and sensibility, again with variations in measurement
protocols. The mean follow-up time ranged from 2 weeks to 17 years.
Conclusions: There is little consistency in the reporting of outcomes for interventions in patients with Dupuytren’s
disease, making it impossible to compare the efficacy of different treatment modalities. Although there are
limitations to the existing generic patient reported outcomes measures, a combination of these together with a
disease-specific questionnaire, and physical measures of active and passive individual joint Range of movement
hould be used for future outcomes studies. As Dupuytren’s© 2013 Ball et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Dupuytren's disease (DD) is a common fibroproliferative
disorder of the hand affecting 4-6% of the population in
northern Europe [1]. It is characterized by the progres-
sive thickening and shortening of the palmar fascia,
resulting in the formation of cords, flexion deformities
of the digits, and hence loss of range of motion, particu-
larly functional extension [2]. DD often restricts a pa-
tient’s ability to undertake daily activities of living,
depending on the location, extent and severity of disease.
The deterioration in hand function is the main motiv-
ator for patients seeking treatment [3].
DD is progressive, advancing at varying rates, and may
occur bilaterally. It can also recur in the same digit fol-
lowing treatment or appear at another site in the hand
(disease extension). Furthermore, the effects of recur-
rence are not uniform and some patients may opt to
have further intervention. Therefore, the development of
a uniform set of measures to accurately assess functional
impairment has proved challenging.
Most patients with early disease, i.e. before the develop-
ment of digital contractures, are left untreated, although ra-
diation [4] and steroid injections [5] have been used.
Currently, the mainstay of treatment for patients with
established flexion deformities is surgery in combination
with hand therapy. The aim of surgical procedures for DD
is to preserve and, if possible, improve hand function. Sur-
gery comprises either the division (fasciotomy) or removal
(fasciectomy or dermofasciectomy) of the diseased tissue.
Needle fasciotomy divides the cord in a minimally invasive
manner. However, recurrence is common, with one study
[6] reporting a rate of 84.9% at 5 years following needle
fasciotomy compared with 20.9% following limited surgical
fasciectomy. Discontinuity of the cords may also be
achieved enzymatically, with 77% of metacarpophalangeal
joints and 40% of proximal interphalangeal joints being
corrected to within 5 degrees of full extension [7]. However,
like needle fasciotomy, recurrence rates are high, affecting
56% of PIP joints and 27% of MCP joints at 3 years [8].
The need for a systematic review on outcomes used in
Dupuytren’s disease
The optimal treatment in DD remains controversial, in
large part due to the lack of evidence based on good
quality clinical outcomes studies. Not only is there a
paucity of research reporting functional outcomes data
for DD but also a lack of consensus on the parameters
that should be used. Traditionally, the evaluation of
treatment success for DD has largely been determined
by clinical examination and physical measures, although
improvement in physical measures does not necessarily
reflect function [9]. Functional outcome measures spe-
cifically assess the consequences of impairment in daily
activities. A recent systematic review of efficacy andsafety of DD surgery in European patients noted that the
commonest outcome measure was improvement in
mean joint contracture [10]. However, hand function
outcomes were not included in this review. The scarcity
of studies reporting functional outcomes following treat-
ment for DD has previously been highlighted [11] and
noted in a review of surgical treatments for primary DD
[12]. More recent studies have monitored functional
outcomes using patient reported outcome measures
(PROMs), which have been recognised as an important
measure of the effectiveness of care from the patient’s
perspective [13].
The aim of this review is to identify and determine the
relevance and efficacy of outcomes measures used to as-
sess change in hand function following treatment DD by
surgery, needle fasciotomy or collagenase injection. This
will provide an evidence base to inform the selection of
appropriate measures for future research on the man-
agement of patients with DD.
Methods
Search strategy
The search strategy and search terms were based on a Par-
ticipants, Intervention, Comparison, Outcomes and Study
design (PICOS) [14] (Additional file 1: Table 1). We in-
cluded studies published over the last 20 years in the English
language of adults who had surgery, needle fasciotomy or
collagenase injection for primary or recurrent DD where
outcomes were monitored using standardised PROMs, func-
tional tests or physical measures as opposed to recording
unsubstantiated improvement. Functional outcomes mea-
sures reported in randomised and non-randomised con-
trolled clinical trials, prospective and retrospective case
series were included. Non-invasive interventions including
radiotherapy, steroid injection alone, splinting and skeletal
traction were also excluded, as were case studies, conference
abstracts and letters. There was no restriction regarding the
time that patients were monitored post-intervention.
Search methods for identification of studies
A literature search was performed in July 2012 using
subject heading and free-text terms. Three databases,
Ovid Medline, Embase and CINAHL (via EBSCOHost)
were searched from 1992 to July 2012. PubMed was also
searched from September 2010 - July 2012 to capture
electronic publication ahead of print studies not in-
cluded in Ovid Medline. Searches were limited to studies
in English. Search results were imported into an End-
Note library and 616 publications were identified for
title/abstract review after removal of duplicates.
Two authors (CB, ALP) individually screened the stud-
ies using the study eligibility tool to identify studies for in-
clusion with information gained from the electronic
databases (minimum title). Where necessary, consensus
was achieved by reviewing the full text. Five hundred and
twenty five studies were excluded, resulting in 90 articles
meeting the inclusion criteria. Following detailed assess-
ment of the included articles, one further publication was
identified from their reference lists. The study selection
process is summarised in Additional file 2: Figure 1.
Data collection and analysis
Data on intervention, population and outcomes were
collected and tabulated on a Microsoft Excel (Microsoft,
Seattle) spreadsheet. Amalgamation of data for statistical
analysis was not possible due to the heterogeneity of the
Patient Evaluation Measure (PEM) (n=1). Two used the
Michigan Hand Outcomes Questionnaire (MHQ) in
addition to the DASH. A recently developed disease-
specific questionnaire, Unité Rhumatologique de Affec-
tions de la Main scale (URAM), was utilised by one
study [15] and 8 used other self-report measures such as
return to work or self-rated disability. A further 5
reported the use of function PROMs but did not present
the results [16–20]. The use of PROMs is summarised in
Figure 1.
The DASH questionnaire [21] was the most frequently
used function PROM (11 studies) but only 6 studies
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to illustrate the variety of functional outcome measures
used and the quality of the data. Where available, nu-
merical data are presented as means with range and
standard deviation.
Results
Clinical study design
Of the 91 included studies, 66 pertained to surgery, 16 to
needle fasciotomy and 9 to collagenase injection. All 9
publications reporting the outcomes of collagenase injec-
tion were randomised controlled trials or prospective stud-
ies. Many studies reporting surgery (n=29, 43.3%) were
retrospective reviews. Eighteen publications reporting out-
comes for surgery and 4 needle fasciotomy studies were
prospective. In 17 studies (18.7%) it was not possible to es-
tablish whether they were prospective or retrospective in
design and were categorised as ‘unclear’. The functional
outcomes used for each of the three interventions is
summarised in Additional file 3: Table 2.
Patient reported outcome measures (PROMs)
Measures of function
Twenty-two studies included patient reported data using
function PROMs with 13 using validated region-specific
questionnaires: the Disability of Arm, Shoulder and
Hand (DASH) (n=11), Quick-DASH (n=1) and theFigure 1 Use of function patient reported outcome measures accordi
collagenase injection.presented calculated pre-and post-treatment data [22–27]
(Table 1).
The DASH score is calculated using the formula ((sum
of n responses) -1)/nx25), where n represents the num-
ber of completed items, resulting in an aggregate calcu-
lated score ranging from 0 to 100, with a higher score
indicating a greater level of disability [21]. Mean pre-
treatment values ranged from 12.1 (SD 2.9) [23] to 24
(SD 20) [25] and post-treatment from 3.44 (range 0 to
52.5) [28] to 8 (SD 8) [25]. It should be noted that a fur-
ther two studies presented uncalculated or ‘raw’ DASH
scores evidenced by reporting a score in excess of 100
[29] or interpreting a score of 30 as ‘no self-perceived
disability’ [30] and were excluded as presentation of the
data in this way precluded comparison with other
studies.
Two studies additionally used the Michigan Hand
Questionnaire (MHQ) [23,25]. The MHQ [31] is scored
using an algorithm described in the MHQ codebook
[32]. Scores can range from 0–100 for each hand, with
higher values representing better function, except for
pain, where a higher score indicates more pain. Both
studies reported significantly improved global MHQ
scores compared to pre-operative scores.
One study utilised the Patient Evaluation Measure
(PEM) [33]. The PEM is a validated PROM [34] compris-
ing 3 sections combining hand function and satisfactionng to intervention surgery, needle fasciotomy and
eon
on
ont
sing
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pre- and post-operative data)
Author No. study subjects Assessment schedule (range)
Engstrand
et al.
60 Pre and 3 months
Herweijer* 46 Pre and mean 10 (7 to 13) months
Jerosch-
Herold,
148 Pre, 3, 6 and 12 months
Johnston
et al. *
17 pre-op and 16 post-
op
Pre, 3 and mean of 14 (11 to 16) m
Skoff, 30 (cohort of 10 and 20
subjects respectively)
Pre and average of 42 (37 to 48) m
and average 32 (range 24 to 36) m
Sobierajska 35 Pre, 1 and 3 months
Van
Rijssen (a),
50 PNF Pre, 1,2,3,4 and 5 weeks
47 LF
Zyluk 54 Pre, 3 and 12 months
*Also reported MHQ data in same scheduling.
Number of study subjects and timing of post treatment assessment in studies uwith outcome and treatment by asking patients to com-
pare their current versus pre-treatment hand function.
The questionnaire is not administered before treatment.
The score is calculated by summing the value of the 14
questions in parts 2 and 3 of the PEM and expressed as a
percentage of the maximum possible score, with 0%
representing a ‘normal’ hand. The study assessed hand
function and disability in a retrospective postal audit at a
mean follow-up of 27 months (SD 8, range not given) and
found a correlation with patient assessed deformity. PEM
scores ranged from 9 (SD14, range not given) for patients
with no deformity to 57 (SD 25, range not given) for se-
vere deformities at both the MCP and PIP joints.
Mean final follow-up times for function PROMs
ranged from 3 months [22,35] to 4.5 years [36]. Final
follow up times for studies recording pre- and post-
operative DASH scores varied between 5 weeks and 48
months.
Patient satisfaction
Eighteen studies used patient satisfaction as an outcome,
with no single method used consistently. These included
a visual analogue scale of satisfaction [27,37–39], satis-
faction with treatment [40,41], as well as various de-
scriptive responses such as ‘very pleased, pleased or
disappointed [42], or ‘rating of overall clinical success’
[39]. Follow-up times ranged from 1 month [43] to me-
dian of 4 years (range 1 – 15) [41].nt assessment in studies using DASH and reporting
Pre-op Post-op (final)
Mean
(range/ SD)
Mean (SD)
17 (7–28) 7 (3–12
interquartiles)
12.1 (12.9) 6.6 (8.8)
16.4 (15.1)
Splint group
7 (14.6) Splint group
15.4 (13.2) No
Splint group
6 (9.2) No Splint
group
ths 24 (20) 8(8)
ths for cohort of 10 subjects. Pre
hs for cohort of 20 subjects.
37 ‘mild
disability’ raw
data
30 ‘no self-perceived
disability’ raw data
17.5 (14.88) 15.02 (15.25)
16 (14) PNF
group
9 PNF group
14 (12) LF
group
16 LF group
54 (30 to 103)
raw data
32 (30 to 104) raw
data
DASH and reporting pre- and post-operative data.Tests of function
Two studies [44,45] utilised the Sollerman hand function
test. The Sollerman test comprises 20 unilateral and bi-
lateral hand tasks performed using standardised hand
grip patterns intended to reflect normal function in ac-
tivities of daily living [46]. Performance is graded by the
examiner according to the quality of the grip and the
time taken to perform each task. The scores range from
0 to 80, with normative values of 80 for the dominant
hand and 77 to 80 for the non-dominant hand. Scores
were 72.8 (range not reported) pre-treatment and 78.03
(range not reported) 6 months post-treatment [44]. A
second study at the same centre reported scores of 71
(range 62 to 80) pre-treatment and 77 (range 66 to 80)
6 months post-treatment [45]. Neither publication
reported whether the improvement was statistically
significant.
Physical measures
ROM
Range of movement was the most frequent measure and
was reported in all 91 studies. However, the methods of
recording range of movement varied, with 17 different
descriptors. Table 2 summarises the range of motion
reporting of all studies. Techniques most commonly
used in order of frequency included measurement of
flexion contracture (n=24), joint extension deficit (n=18),
Tubiana system which grades the DD contracture into
9 studies reported more than 1 method)
91
udy reference number Frequency
6,17,20,30,37,39,48–65] 24
7,18,36,38,45,55,66–77] 18
,20,25,30,51,53,66,70,78–85] 16
5,27,43,60,67,71,75,79,86–93] 16
9,33,40,44,47,64,77,78,94–99] 14
,7,27,43,61,78,85–87,89,90,100] 12
4,97,101–104] 6
3,24,35,41,66,70] 6
9,105–107] 4
7,86,87] 3
7,7
9,1
6,3
2,1
2]
09]
5] 1
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MCP and PIP joints (n=16), active flexion and extension
Table 2 Range of motion reporting: all studies n=91 (NB. 2
Range of motion reporting n=
Description St
Flexion contracture [1
Joint extension deficit [1
Active flexion and extension of joint [7
Tubiana Grading system [1
Author defined category [1
Passive extension deficit [6
Fixed flexion deformity [9
Total Active Motion [2
Flexion deformity [9
Composite flexion [2
Flexion deficit [2
Extension contracture [2
Total lack of active extension [2
Percentage change [4
Total digital extension [2
Total active extension deficit [1
Total lack of active flexion [3
Additional file 1: Table 1: Search strategy and search terms using PICOS analysis.deficit (n=16) and the use of author defined categories
such as ‘improved’ or graded according to degree of con-
tracture defined by the author (n=14). Twelve other
methods were used in 35 studies (Table 2). Follow-up
times post treatment ranged from 2 weeks [27] up to 17
years [47].
Grip and Pinch strength
Measurements of grip strength or pinch grip were
presented in 11 studies but only 3 reported pre- and
post-intervention data [23,25,29] and 3 gave a descriptor
of post-treatment outcomes, for example ‘no significant
change or deterioration’ [20,48,66]. Follow-up times
ranged from a median of 81 days [66] to a mean of 3.5
years [28].
Sensibility
Of 11 studies that reported sensibility testing, only one
presented pre- and post-operative data [23]. Sensibility
was tested using two-point discrimination (2PD) in 6
studies, Semmes Weinstein Monofilaments (SWM) by 1
group and assessment of light touch by another using
the fingertip. No collagenase injection studies recorded
sensibility. Three studies reported testing sensibility but
data were not presented [16,86,87]. Follow-up times
after treatment ranged from means of 10 months [23] to
4.4 years [105].Figure 2 summarises the frequency of the various
functional outcomes used before and after each type of1] 2
08] 2
5] 2
01] 2
1
1intervention.
Discussion
Our review highlights the heterogeneity of outcome
measures used for reporting the results of treatments for
DD and the challenges faced when attempting to inter-
pret data to determine best practice. Furthermore, many
studies reported in insufficient detail how data were
Figure 2 Frequency of outcome measures used and number of
studies that measured before and after treatment.
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follow-up times have been highlighted previously [12].
The importance of utilising a set of commonly ac-
cepted outcome measures that are validated is para-
mount so that the natural history of the disease as well
as treatment success can be monitored at both the pa-
tient and population level to enable meaningful compari-
sons between treatment modalities. Therefore, there is
an urgent need for a common consensus regarding the
reporting of outcomes data collected in high quality
studies.
Patient reported outcome measures
PROMs, although subjective, are critical measures of
treatment efficacy as patient perceived benefit is the ul-
timate goal of treatment. They should, therefore, supple-
ment data derived from physical measures as they
provide the context of the impact on function for the in-
dividual. PROMs including functional measures have
gained prominence with the current emphasis on patient
centred clinical practice. Yet, no publication of collage-
nase injections used PROMs as an outcome and only 15
publications reporting surgical outcomes used function
PROMs. Only one RCT reported outcomes using func-
tion PROMs [24].
The DASH questionnaire is a 30-item self-rated
region-specific disability and symptom scale outcome
measure. It was the most commonly used function out-
come measure but may lack the sensitivity to detect sig-
nificant improvement following surgical or injection
treatment for DD due to a ‘flooring effect’, that is rela-
tively low pre-treatment scores resulting in a reduced
potential for improvement [24]. It is difficult to be cer-
tain whether this represents a genuine problem as only 6
studies reported pre-treatment DASH scores, although
all showed comparatively low values. The normal mean
value for the DASH questionnaire reported by the
American Academy of Orthopaedic Surgeons [110] was
10.10 (+/− 14.68 SD). All publications reporting pre-
and post-operative data showed a reduction in post-
operative scores, indicating an improvement in function
compared with pre-operative levels, but this reached sig-
nificance in only two studies [22,23]. A difference of 15
points is considered to be the minimal clinically import-
ant difference (MCID) indicating an improvement [111].
However, the exact figure is controversial and may vary
according to the upper limb disorder being considered.
No studies achieved a MCID equal to or more than 15
points and only two studies showed a MCID of 10
points [22,25], which may in part be attributed to the
relatively low pre-treatment scores. Additionally, caution
is advised when applying MCIDs due to difficulties with
variation over time of in the patients’ perception of their
disability [112]. Thus, whilst the evidence for assessingthe outcomes of interventions for DD using DASH indi-
cates that it may be useful, further work is necessary to
determine the level of change that is considered
meaningful.
The Michigan Hand Outcome Questionnaire (MHQ)
is a 37-item region-specific outcome measure that in-
cludes 6 sub-scales of activities of daily living, hand
function, pain, cosmesis, patient satisfaction and overall
function [31]. The MHQ has been shown to detect
change in function following surgery for DD [23,25] and
to correlate with changes in fixed flexion deformity [25].
The MHQ focuses on the hand as compared with the
DASH, which assesses entire upper limb function. Fur-
thermore, unlike DASH, the MHQ assesses the func-
tional impact on each hand separately; this may be
especially relevant to conditions such as DD that can
affect both hands to varying extents. It also includes
questions that may be of greater relevance for people
with DD. For instance, aesthetics are a construct in the
MHQ not included in the DASH and may be relevant
for some patients with DD, for example when shaking
hands [3] or when presenting the hand with the palm
uppermost as when receiving coins.
Whilst the MHQ may appear to be more suitable than
the DASH to assess DD outcomes it is lengthy, compris-
ing 74 questions, and may not always be completed.
Short versions of the DASH and MHQ have recently be-
come available. The Quick-DASH was used by one study
[66] but it is not clear if it is prone to a flooring effect
when used for DD. The use of the short MHQ has not
yet been reported in outcomes studies for DD. Pain,
which is included in both the DASH and MHQ, is sel-
dom reported by people with DD [113] and may reduce
the sensitivity of both tools.
The PEM has been shown to be sensitive to change
when used for patients with scaphoid fractures or carpal
tunnel syndrome [114]. In a study of 100 patients with
various conditions affecting the hand [115], including 15
who had DD, patients were able to complete it more
rapidly than the DASH or MHQ. A sub-analysis of the
results for the patients DD has not been published.
Therefore, it is not possible to assess the sensitivity to
change in the context of DD.
While there are a number of other hand function
questionnaires, these have either been validated for use
with specific conditions such as the ABILHAND for
rheumatoid arthritis, chronic stroke and systemic scler-
osis [116] or do not assess the area affected by DD, such
the Patient Rated Wrist Evaluation (PWRE) [117].
Disease-specific hand function questionnaires are gener-
ally considered to be desirable as they focus on activities
that specifically affect the study population, usually hav-
ing been developed with patient participation. An ex-
ample that has been shown to be sufficiently sensitive to
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syndrome [118]. Recently the Unité Rhumatologique de
Affections de la Main scale (URAM) questionnaire [15]
and Southampton Dupuytren’s Scoring System [119]
have been developed as disease specific questionnaires,
but have not yet been validated by other investigators.
An alternative approach is to ask individual patients to
identify their most restricted activities and when applied
to DD, significant improvement in median scores were
reported [22].
Patient satisfaction
Methods used to report patient satisfaction varied, with
no single measure used consistently. Studies reported
overall satisfaction or satisfaction with surgery but did
not explore the relationship with hand function. One
study of collagenase injection [78] correlated satisfaction
with treatment and improved range of motion at 30 days
after the last injection.
Tests of function
Functional tests are used to provide objective ‘measur-
able’ assessment of function. However, critics question
their ability to accurately reflect function due to the
strict test conditions. Speed of task completion is used
to identify change and does not reflect everyday condi-
tions experienced by the patient. The Sollerman was the
only functional test used to date in patients with DD.
The 2 studies [44,45] using this measure were under-
taken in the same centre in the UK, with both reporting
change. However, lack of information on reliability, val-
idity and sensitivity for patients with DD, together with
lengthy completion time [120] and the need for cumber-
some equipment, may limit widespread use.
Physical measures
Range of movement
Range of motion was the most commonly used outcome
measure and was reported by every study. It is sensitive
to change and benefits from a high inter-rater reliability
for patients with DD [121]. However, the relationship
between the degree of flexion contracture and loss of
function in patients with DD is not necessarily linear
[9,29,122], and the amount of change of motion required
to translate into a significant functional improvement is
unclear and may vary according to the patient and dis-
ease severity prior to treatment.
Although ROM was documented in all studies, the
reporting was not standardised, making comparison be-
tween publications difficult. While studies may appear to
be describing the same measure (joint extension deficit,
fixed flexion deformity, flexion deformity, flexion deficit,
extension contracture), the lack of a standardised meas-
urement protocol means that this cannot be assumed.For example, many studies did not state how hyperexten-
sion was recorded, a common finding at the distal
interphalangeal joint or as a compensatory movement at
the metacarpophalangeal joint (MCPJ) especially for the lit-
tle finger in patients with isolated proximal interphalangeal
joint (PIPJ) contractures. Fixed deformities should be
recorded separately and whether the apparent fixed flexion
at the PIPJ can be overcome by flexing the MCPJ should
be noted.
The grading system originally described by Tubiana
was the joint third most frequently reported measure
used for ROM [123]. Clinically it allows easy identifica-
tion of improvement but not the location of change as it
combines the measures of the MCP and PIP joints.
Therefore, we suggest that if using the Tubiana grading,
it should be supplemented with additional measures to
detail the individual joints at which the improvement
has been achieved. Similarly, composite ROM measures
of finger joints, such as total active motion (TAM), do
not permit identification of change at individual joints.
Grip
Measurements of pinch and grip strength are important
aspects of hand function [124] and have been shown to
have a strong correlation with disability [125]. However,
only 3 of 10 studies that recorded grip or pinch grip
strength presented data before and after treatment. Fur-
thermore, assessment of grip and pinch were often not
standardised. Grip strength is best measured using a
protocol such as that recommended by the American
Society of Hand Therapists. A reliable assessment of grip
strength is important to capture clinical changes in
interventional studies.
Sensibility
Sensibility testing was mainly used to monitor complica-
tions such as inadvertent nerve injury [16,87]. Most au-
thors assumed that participants had normal sensibility
before intervention, with only one recording pre-treatment
values. Although testing using Semmes Weinstein Mono-
filaments has been shown to be a superior measure of
sensibility assessment following nerve injury than static
two point discrimination [126], they were used in only one
study.
Limitations of the review
Excluding articles not published in the English language
may have led to potential bias and heterogeneity of stud-
ies precluded pooling of data for meta-analysis. The in-
clusion of low quality studies presenting retrospective
data may be viewed as a limitation but an exclusive ap-
proach would have resulted in an incomplete picture of
current methods used.
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Studies to date on the outcomes of treatments for pa-
tients with DD are heterogeneous and of relatively poor
quality. It is critical to achieve a consensus regarding
validated outcome measures to monitor disease progres-
sion and treatment success in order to enable compari-
sons between treatment modalities. Subtle deterioration
of hand function with functional adaptation in patients
with DD over time makes this challenging. Therefore, it
is important to use measures that accurately assess glo-
bal and local disability in a sensitive and specific manner
in order to successfully evaluate any change in hand
function as a result of intervention. Change in hand
function is best assessed by a combination of physical
measures and questionnaires [127]. DD can affect mul-
tiple digits of the same hand but can also occur bilat-
erally so comparison with the contralateral hand is not
always possible. Inclusion of more than one hand or fin-
ger per patient and patient drop out resulting in varying
numbers at follow-up represent possible sources of bias.
Based on our findings we recommended the use of a
region specific questionnaire such as the MHQ and a
validated disease specific PROM like the URAM. A use-
ful addition would be designation of tasks important to
each patient and indicating on a linear scale the degree
of difficulty before and after treatment. Patient satisfac-
tion should be assessed using a valid and reliable ques-
tionnaire such as the Picker questionnaire [128] or PEM.
Physical measures of joint ROM, grip and sensibility
should be included, with ROM measured before and
after treatment using a standardised protocol. We rec-
ommend recording measurement of active flexion and
extension of each joint and including whether an ap-
parent fixed flexion deformity of the PIPJ can be over-
come with passive flexion of the MCPJ. Grip strength
should be measured using a validated instrument, such
as the Jamar dynamometer according to a standardised
protocol. Assessment of sensation using Semmes
Weinstein Monofilaments should be used to monitor
complications.
Hand function may also be compromised by recurrent
disease. Scheduling of follow-up assessments may differ
between surgery and other less invasive interventions
but final follow-up time should be standardised to cap-
ture recurrence and understand how this affects function
[129]. Following needle fasciotomy and collagenase in-
jection initial improvement in range of motion and satis-
faction may compare favourably with surgery in the
short-term but recurrence may compromise function
and satisfaction in the long-term.
A comprehensive and consistent approach will enable
the development of a robust and reliable evidence base
upon which to base best clinical practice for the treat-
ment of patients with Dupuytren’s Disease.Additional files
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